Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Star Roe

Nurse Practitioner, Family Barboursville, WV Nurse Practitioner

NPI 1790393577 CMS profile 10528456

6171 Childers Rd, Barboursville, WV 25504

Open in the dashboard

General payments

$55,212

658 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Star Roe of Barboursville, WV is reported in the CMS Open Payments database as having received $55,212 across 658 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,201 152
2024 General $12,234 105
2023 General $26,863 171
2022 General $3,780 132
2021 General $2,133 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Star Roe
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Star Roe were reported at $10,201. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Star Roe Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,133 $124 $35–$379 $132
2022 $3,780 $141 $44–$430 $149
2023 $26,863 $154 $49–$476 $160
2024 $12,234 $165 $51–$504 $164
2025 $10,201 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $47,293 234 payments
  2. Jazz Pharmaceuticals Inc. $1,788 97 payments
  3. Harmony Biosciences LLC $952 60 payments
  4. Alkermes, Inc. $714 39 payments
  5. Teva Pharmaceuticals USA, Inc. $679 38 payments
  6. Axsome Therapeutics, Inc. $653 29 payments
  7. Otsuka America Pharmaceutical, Inc. $536 28 payments
  8. ITI, Inc. $495 26 payments
  9. Corium, Inc. $430 31 payments
  10. Lundbeck LLC $180 11 payments
  11. Other $1,491 65 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $41,500 35 payments
  2. Food and Beverage $11,494 605 payments
  3. Travel and Lodging $1,496 9 payments
  4. Education $722 9 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $38,719 179 payments
  2. VRAYLAR Neuroscience $8,289 33 payments
  3. XYWAV $772 35 payments
  4. LYBALVI Cns $647 36 payments
  5. REXULTI $536 28 payments
  6. CAPLYTA $441 24 payments
  7. Azstarys $430 31 payments
  8. LYBALVI Cns $430 22 payments
  9. LYBALVI Cns $430 22 payments
  10. LYBALVI Cns $430 22 payments
  11. Other $5,692 303 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 54 drugs

Part D claims

2,548

Median for Nurse Practitioner: 389

Drug cost

$713,576

Median for Nurse Practitioner: $21,885

Branded share of claims

20.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Xr Deutetrabenazine Brand 22 $239,328
Vraylar Cariprazine Hcl Brand 100 $197,378
Austedo Deutetrabenazine Brand 12 $95,716
Spravato Esketamine Hcl Brand 39 $57,098
Rexulti Brexpiprazole Brand 21 $36,144
Sunosi Solriamfetol Hcl Brand 16 $13,346
Trintellix Vortioxetine Hydrobromide Brand 13 $10,311
Lurasidone Hcl Generic 14 $8,672
Vyvanse Lisdexamfetamine Dimesylate Brand 20 $7,675
Modafinil Generic 43 $7,383

The 10 drugs with the highest cost, of 54 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$11,953

Medicare's payments for the services billed

Medicare patients

65

Average age 63

Services billed

175

46 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 63%
Arthritis 62%
Diabetes 31%
Chronic kidney disease 23%
Ischemic heart disease 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$10,703 100 —
Austedo XR
$221 34 —
Sunosi
$186 16 —
REXULTI
$172 21 —
XYWAV
$125 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

658 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record